Compare LINK & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINK | PMN |
|---|---|---|
| Founded | 1984 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.7M | 84.1M |
| IPO Year | 2007 | 2022 |
| Metric | LINK | PMN |
|---|---|---|
| Price | $3.27 | $4.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | N/A | ★ $42.27 |
| AVG Volume (30 Days) | 21.0K | ★ 350.4K |
| Earning Date | 11-24-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.83 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,890,000.00 | N/A |
| Revenue This Year | $40.45 | N/A |
| Revenue Next Year | $19.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.81 | N/A |
| 52 Week Low | $2.66 | $0.29 |
| 52 Week High | $6.50 | $27.40 |
| Indicator | LINK | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 30.80 | 32.67 |
| Support Level | $2.87 | $2.78 |
| Resistance Level | $3.38 | $15.05 |
| Average True Range (ATR) | 0.30 | 1.21 |
| MACD | -0.05 | -0.26 |
| Stochastic Oscillator | 20.13 | 13.58 |
Interlink Electronics Inc is a provider of sensing technologies and printed electronics solutions that enable Human-Machine Interface (HMI) devices and Internet-of-Things (IoT) applications. Its broad product and technology portfolio spans force and touch sensors, piezoelectric sensors, rugged HMI sensors, wearable and textile-based sensors and electrochemical gas and environmental sensors, along with instruments and fully integrated systems based on its sensor technologies. It serves blue-chip customers and emerging companies across diverse end-use markets, including medical, industrial, automotive, consumer electronics, wearables, environmental monitoring, and specialty applications. It operates in single segment: the design, development, and manufacture of sensor technologies.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.